Imepitoin

Overview

Imepitoin (Pexion®) is a GABAA receptor partial agonist approved in the United States for the treatment of noise aversion in dogs. In the United Kingdom and European Union, it is also licensed for the reduction of anxiety and fear associated with noise phobia and as initial therapy for generalized seizures due to idiopathic epilepsy in dogs, although the current UK indication for idiopathic epilepsy is for use after careful evaluation of alternative treatment options.

Clinical studies have demonstrated efficacy for noise aversion and storm phobia in dogs. For canine idiopathic epilepsy, studies have reported variable results when compared with phenobarbital, with some demonstrating comparable efficacy and fewer adverse effects, while others reported better seizure control with phenobarbital. Current clinical consensus supports imepitoin as a monotherapy for idiopathic epilepsy, whereas evidence supporting its use as add-on therapy remains limited.

A small study in cats found that imepitoin administered at 30 mg/kg twice daily for 30 days was well tolerated and demonstrated preliminary efficacy for idiopathic epilepsy; however, additional studies are needed to establish its safety and efficacy in cats.

Mechanism of Action (MOA): Imepitoin is a low-affinity partial agonist at the benzodiazepine binding site of the GABAA receptor. It potentiates GABAA receptor-mediated inhibitory neuronal activity, thereby reducing neuronal excitability and preventing seizures. Weak inhibition of neuronal calcium channels may also contribute to its anticonvulsant activity. In addition, imepitoin possesses anxiolytic effects.

Indications

Imepitoin is used in dogs for the management of noise-related fear and anxiety and, in some countries, as an anticonvulsant for idiopathic epilepsy. Limited data also suggest potential use in cats with idiopathic epilepsy.

• Noise aversion (dogs): FDA-approved for the treatment of noise aversion associated with predictable loud noise events.
• Noise phobia (dogs): Licensed in some countries to reduce anxiety and fear associated with noise phobia; continuous use for storm-related anxiety is extra-label.
• Other fear and anxiety (dogs): May also be used with a behavior modification plan for anxiety related to social stimuli (e.g., crowds, strangers) or non-social stimuli (e.g., noises, novel items, new environments), once any role of pain has been controlled.
• Idiopathic epilepsy (dogs): Licensed in some countries as initial monotherapy for generalized seizures due to idiopathic epilepsy.
• Idiopathic epilepsy (cats): Preliminary studies suggest potential efficacy and good tolerability, although further studies are needed.

Dosage (Reference)

Dog

Imepitoin is administered orally every 12 hours. For noise aversion, treatment should begin before the anticipated noise event. For idiopathic epilepsy, therapy is initiated at a lower dose and increased gradually based on seizure control.

Cat

Clinical data in cats are limited. The reported dosage is based on a small study evaluating idiopathic epilepsy.

Warnings & Precautions

Imepitoin should be used only in appropriate canine patients, as its safety has not been established in several populations. Careful patient selection and monitoring are recommended, particularly in animals with concurrent disease or behavioral concerns.

• Contraindications: Do not use in animals with hypersensitivity to imepitoin, severely impaired hepatic function, severe renal disease, or severe cardiovascular disorders.
• Limited safety data: Safety has not been established in dogs weighing less than 2 kg (4.4 lb), dogs younger than 5 months of age, or dogs with renal, hepatic, cardiac, gastrointestinal, or other systemic disease.
• Behavioral changes: Imepitoin may cause disinhibition of fear-based behaviors, which can result in changes in aggression. Patients should be observed carefully during treatment.
• Discontinuation: In dogs receiving imepitoin for seizure control, abrupt withdrawal may result in mild behavioral or muscular signs. Gradual dose reduction should be considered when discontinuing therapy.
• Tapering protocol: One reported withdrawal schedule reduced the dosage to 20 mg/kg PO every 12 hours for 1 month, then 10 mg/kg PO every 12 hours for 1 month, followed by 10 mg/kg PO once daily for 1 month.
• Cluster seizures and status epilepticus: Efficacy has not been investigated in dogs with cluster seizures or status epilepticus, so imepitoin should not be used as their primary treatment.
• Switching antiepileptic drugs: Response varies and some dogs do not respond, with seizure frequency increasing in some non-responders; consider carefully before switching a stabilized dog to imepitoin, and make any change between antiepileptic drugs gradually under clinical supervision.
• Breeding, pregnancy, and lactation: Reproductive safety is not known; imepitoin is not recommended in male breeding dogs or in female dogs during pregnancy and lactation.

Drug Interactions

Imepitoin has a low potential for clinically significant drug interactions. Reported and theoretical interactions are limited, but appropriate monitoring is recommended when used with other medications.

• Phenobarbital: Concurrent administration has been reported in a small number of dogs without harmful clinical interactions.
• Highly protein-bound or enzyme-inducing drugs: Clinically significant interactions are not expected due to imepitoin’s low drug interaction potential.
• Flumazenil: May antagonize the anxiolytic and anticonvulsant effects of imepitoin.
• Benzodiazepines and other CNS depressants: Additional sedation may occur in dogs given other CNS depressants, especially benzodiazepines; there is no evidence that imepitoin prevents the effect of benzodiazepines given for acute seizure treatment (e.g., status epilepticus).

Side Effects & Overdose

Side Effects

Adverse effects are generally mild to moderate and are most commonly related to the central nervous system or gastrointestinal tract. Some effects occur more frequently during the early stages of treatment.

• Neurologic effects: Ataxia, lethargy, somnolence, hyperactivity, apathy, and aggression have been reported.
• Gastrointestinal effects: Emesis, diarrhea, increased appetite (polyphagia), decreased appetite, and hypersalivation may occur.
• Urinary effects: Polyuria and polydipsia have been reported.
• Ocular and sensory effects: Prolapsed nictitating membrane, decreased sight, and increased sensitivity to sound have been observed.
• Laboratory changes: Mild increases in plasma creatinine, cholesterol, and liver enzyme activities have been reported. These changes generally remained within reference ranges and were not associated with clinically significant findings.
• Skin lesions: Reported in one dog following a dose increase after 5 months of treatment.
• Cats: The most commonly reported adverse effects were emesis, lethargy, and decreased appetite. Hypersalivation was more common at higher doses; in a randomized trial in cats with idiopathic epilepsy, adverse effects were primarily ataxia and increased ALT activity, suggesting a potential hepatic effect.

Overdose

Repeated overdoses of up to five times the highest recommended dose have been evaluated in dogs. Most adverse effects were reversible and resolved with supportive care.

• Central nervous system effects: Loss of righting reflex, decreased activity, eyelid closure, tremors, nystagmus, lacrimation, and dry eye.
• Cardiovascular effects: Reversible prolongation of the QT interval.
• Weight gain: Observed in dogs receiving repeated overdoses.
• Management: Most cases resolve within 24 hours with supportive and symptomatic treatment.
• Flumazenil: May potentially be used to reverse severe CNS effects associated with overdose and to eliminate the anticonvulsant action of imepitoin.

Key Notes

Practical clinical points to optimize the use of imepitoin in dogs and cats:

• Monotherapy preference: Current clinical consensus supports imepitoin as monotherapy for canine idiopathic epilepsy, while evidence for add-on therapy remains limited.
• Administration: The medication is best administered on an empty stomach about 12 hours apart. If vomiting occurs after dosing, it may be given with food.
• Consistent dosing: To maintain therapeutic effectiveness, imepitoin should be administered regularly as prescribed and not intermittently.
• Long-term monitoring: For prolonged therapy, baseline and periodic assessment of renal and hepatic analytes should be considered.
• Treatment monitoring: Monitor clinical response together with changes in appetite, activity level, polyuria/polydipsia, ataxia, lethargy, and somnolence during therapy.